A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis
Gauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al. · 2009
Read A New Mixed-Backbone Oligonucleotide against Glucosylceramide Synthase Sensitizes Multidrug-Resistant Tumors to Apoptosis by Gauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006938.txt.
Description
Gauri Patwardhan, Qian-Jin Zhang, Dongmei Yin, and colleagues tested a new cancer drug aid in PLOS ONE in 2009. Many tumors resist chemotherapy, and an enzyme called glucosylceramide synthase helps them do it. The enzyme boosts a process that limits drugs such as doxorubicin. The team built a mixed-backbone oligonucleotide aimed at that enzyme.
Their short synthetic strand was designed to lower the enzyme's activity. They tested it on multidrug-resistant tumors. The treatment made resistant cells more likely to die by apoptosis. Blocking this enzyme could restore the power of standard cancer drugs in tumors that no longer respond.
Catalog record
| CREATOR | Gauri A. Patwardhan, Qian-Jin Zhang, Dongmei Yin et al. |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006938